Roche Acquires Good Therapeutics to Gain PD-1-regulated IL-2 Program
September 7, 2022
Roche has entered into a definitive merger agreement to acquire Good Therapeutics, a Seattle-based privately held biopharmaceutical company, for an upfront $250 million plus milestone payments. The deal gives Roche rights to Good Therapeutics' conditionally active PD-1-regulated IL-2 program and an exclusive right to the platform for developing PD-1-regulated IL-2 receptor agonists; the transaction is expected to close in Q3 2022 subject to HSR clearance.
- Buyers
- Roche
- Targets
- Good Therapeutics
- Industry
- Biotechnology
- Location
- Washington, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.